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Available online xxxxBackground: Sudden cardiac death (SCD) due to ventricular arrhythmias (VA) is an important mode of death in
adults with congenital heart disease (CHD). Risk stratiﬁcation is difﬁcult in this heterogeneous population.
Insertable cardiac monitors (ICM) may be useful for risk stratiﬁcation. The purpose of the present study was to
evaluate the use of ICM for the detection of VA in adults with CHD.
Methods: In this prospective single-center observational studywe included consecutive adults with CHDdeemed
at risk of VA who received an ICM betweenMarch 2013 and February 2019. The decision to implant an ICMwas
made in a Heart Team consisting of a cardiac electrophysiologist and a cardiologist specialized in CHD.
Results:A total of 30patients (mean age, 38±15 years; 50%male) received an ICM.During amedian follow-up of
16 months, 8 patients (27%) had documented nonsustained VA. Of these 8 patients, 3 (10%) received a prophy-
lactic ICD. Furthermore, ICM-detected arrhythmiaswere present in 22 patients (73%) leading to a change in clin-
ical management in 16 patients (53%). Besides the patients receiving an ICD, 10 patients (33%) had a change in
their antiarrhythmic drugs, 6 patients (20%) underwent an electrophysiology study, and 1 patient (3%) received
a pacemaker.
Conclusions: The detection of VA by the ICMcontributed to the clinical decision to implant a prophylactic ICD. Fur-
thermore, ICM-detected arrhythmias led to important changes in the clinical management. Therefore, long-term
arrhythmia monitoring by an ICM seems valuable for risk stratiﬁcation in adults with CHD.
© 2020 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Congenital heart disease1. Introduction
Sudden cardiac death (SCD) is an important mode of death in adults
with congenital heart disease (CHD) and ismainly driven by ventricular
arrhythmias (VA) [1–4]. Identiﬁcation of patients with CHD at risk for
VA is important to determine which patients may beneﬁt from a pro-
phylactic implantable cardioverter-deﬁbrillator (ICD). Risk stratiﬁcation
is hampered by the lowpredictive value of clinical risk factors [5]. This is
not surprising considering Bayes theorem and the low absolute inci-
dence of SCD in adults with CHD [6]. For patients with tetralogy of Fallot
there is some guidance on selecting patients for a prophylactic ICD [7,8].
In other CHD lesions, the decision is challenging and the indication for
an ICD is largely based on systemic ventricular dysfunction, syncope
and/or documented VA. Thedecision to implant an ICD is also hampered
by potential ICD complications, such as shocks, device or lead malfunc-
tion, inappropriate shocks, and psychological burden [9–11].rasmus MC, University Medical
dam, the Netherlands.
eliability and freedom from bias
. This is an open access article under
ling, D.A. Theuns, et al., Early
rnal of Cardiology, https://doConsidering the clinical relevance of documented VA for risk stratiﬁ-
cation, we adopted a strategy focusing on early detection of VA using
insertable/implantable cardiac monitors (ICMs). ICM-detected VA may
provide a tipping point in decision-making in patients who are consid-
ered at risk of SCDbutwhodonot qualify for an ICD according to current
guidelines. Long-term arrhythmiamonitoringusing ICMs already has an
established role in patients with recurrent syncope [12]. In themost re-
cent ESC Syncope guidelines there is an expanding role for ICMs for risk
stratiﬁcation in patients with primary cardiomyopathy or inheritable
arrhythmogenic disorders, but not for patients with CHD [13]. The pur-
pose of the present study was to evaluate the strategy of using ICMs for
the early detection of VA in adults with CHD who are deemed at risk of
VA based on their clinical proﬁle.
2. Methods
2.1. Study design
The Early Detection of Ventricular Arrhythmias in adults with Congen-
ital Heart Disease using an insertable cardiac monitor (EDVA-CHD) study
is a prospective observational study which included consecutive adultsthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
detection of ventricular arrhythmias in adults with congenital heart
i.org/10.1016/j.ijcard.2020.02.009
2 R. Sakhi et al. / International Journal of Cardiology xxx (xxxx) xxxwith CHD who received an ICM between March 2013 and February
2019. The starting date was chosen based on the availability of the Re-
veal LINQ (Medtronic Inc.,Minneapolis,MN, USA) in our center. Patients
who were deemed to be at risk of VA by their treating physician were
eligible for an ICM. The reason for monitoring could be a combination
of symptoms (e.g., (near) syncope, palpitations), prior nonsustained
VA, wide QRS, and/or systemic ventricular dysfunction. The decision to
implant an ICMwasmade in aHeart Teamconsisting of at least a cardiac
electrophysiologist and a cardiologist specialized in CHD. The studywas
approved by the institutional review board of the ErasmusMedical Cen-
ter. Our center is a tertiary referral center with the largest population of
adults with CHD in the Netherlands.
2.2. Device programming and follow-up
All ICMs were implanted subcutaneously as recommended by the
manufacturer using the incision and insertion tool. Furthermore, all pa-
tients received a handheld activator to indicate their symptoms when
necessary. The ICMwasusually programmed according to local settings:
tachycardia-detection was set to 176 bpm for 16 beats; bradycardia-
setting to 30 bpm for 8 beats; pause-setting to 4.5 s; and atrial ﬁbrilla-
tion (AF) setting to ‘AF only’. Based on the implanting physician prefer-
ences other settings could be programmed. All devices were connected
to the Medtronic CareLink network for remote monitoring. Patients
were discharged on the same day of implantation. Ten days after im-
plantation the patients were seen at the out-patient clinic to check
their wound and to interrogate the ICM. Afterwards, the patients were
seen regularly at the outpatient clinic according to routine patient
care. ICM check-ups were performed at the outpatient clinic every
6 months or earlier when necessary based on symptoms or transmitted
episodes. Remote monitoring was performed on a daily basis during
weekdays.
2.3. Classiﬁcation of episodes and endpoints
All patient activated episodes and automatically detected episodes
were classiﬁed. In the case of an inappropriate automatically detected
episode, the cause of inappropriate detection was speciﬁed, if possible.
The primary endpoint of the present studywas the occurrence of VA.
A regular broad complex tachycardia was considered a VA if therewas a
sudden onset and a change in theQRSmorphology in comparison to the
baseline rhythm (Fig. 1A). An irregular broad complex tachycardia was
considered a VA if there was a sudden onset and a polymorphic QRS
morphology. A regular broad or small complex tachycardia was consid-
ered a supraventricular tachycardia (SVT) if there was a sudden onset
and no change in QRS morphology (Fig. 1B). In the case of doubt, a sec-
ond electrophysiologist was consulted for the ﬁnal diagnosis.
The secondary endpoint was the occurrence of other arrhythmias
during follow-up. Finally, it was established whether a detected ar-
rhythmia resulted in a change in patient management (‘actionable
event’).
2.4. Statistical analysis
Continuous data are presented as mean ± standard deviation or as
median with corresponding 25th and 75th percentile, as appropriate.
Categorical variables are presented by frequencies and percentages. Sta-
tistical analyses were performed using SPSS version 21.
3. Results
3.1. Study population
A total of 30 CHD patients (mean age, 38 ± 15 years; 50% male) re-
ceived an ICM during the study period. Baseline characteristics of the
study population are listed in Table 1. The majority of patients hadPlease cite this article as: R. Sakhi, R.M. Kauling, D.A. Theuns, et al., Early
disease using an insertab..., International Journal of Cardiology, https://domoderate or severe complexity CHD. The 3 most common diagnoses
were aortic coarctation, tetralogy of Fallot (TOF) and d-transposition
of the great arteries (d-TGA). The majority of patients had symptoms
at the time of ICM implantation (93%). An impaired systemic ventricular
function was present in 17 patients (57%). A previous nonsustained VA
was documented in 20% of the study population. A detailed patient-
level description of CHD diagnosis, previous cardiac surgery, and reason
for ICM is presented in Appendix A. There were no ICM- or procedure-
related complications.
3.2. ICM-detected episodes
During a median follow-up of 16 months (interquartile range 9–-
21 months), a total of 1689 episodes were transmitted to the CareLink
network system (Table 2). There were 538 (32%) patient-activated epi-
sodes and 1151 (68%) automatically detected episodes. The majority of
patient-activated episodes (88%) comprised sinus rhythmwith or with-
out ectopy, thus, only 12%of patient-activated episodes comprised a sig-
niﬁcant arrhythmia (Table 2).
3.3. Primary and secondary endpoints
During follow-up, 8 patients (27%) developed nonsustained VA. Four
of 8 patients (50%) had a history of nonsustained VA, thus 4 patients
(13%) had a de novo nonsustained VA and 4 patients (13%) had recur-
rent nonsustained VA. In 7 of 8 patients (88%) the VA episodes were de-
tected by patient-activated episodes. Most patients had monomorphic
VA episodes and 1 patient experienced polymorphic VA episodes. Of
the 8 patients with VA, 3 patients had an impaired systemic ventricular
function. Of the 8 patients with VA, 3 patients received a prophylactic
ICD after consultation with their treating physician and 3 patients had
a change in their antiarrhythmic drug therapy. The remaining 2 patients
did not have a change in their clinical management.
A 19-year-old man with surgical corrected Shone's complex (coarc-
tation resection, subvalvular aortic membrane resection, mitral valve
and aortic valve replacement) received a dual-chamber ICD after detec-
tion of recurrent symptomatic nonsustained fast polymorphic VA
(mean CL 240–270ms, maximal 7 beats) 3 months post-ICM implanta-
tion. He received an ICM due to combination of palpitations, exercise-
induced ventricular ectopy, signs of inferiorwall infarction andmild im-
paired systemic ventricular function. After ICD implantation, he experi-
enced two episodes of nonsustained fast polymorphic VA without ICD
therapy during a follow-up of 17 months.
The second patientwho received a dual-chamber ICDwas a 42-year-
old woman with surgical corrected TOF who experienced recurrent
symptomatic nonsustained monomorphic VA (mean CL 490–520 ms,
maximal 11 beats) 3 months post-ICM implantation. She received an
ICM for the combination of palpitations and near-syncope. She did not
experience VA post-ICD implantation during a follow-up of 27 months.
The last patient who received a dual-chamber ICDwas a 44-year-old
man with congenital corrected transposition of the great arteries and
tricuspid valvuloplasty who developed an asymptomatic nonsustained
fast monomorphic VA (mean CL 280 ms, 27 beats) 18 months post-
ICM implantation (Fig. 1A). He received an ICM for a combination of
syncope and dilated systemic ventricle with moderate-to-severe sys-
tolic ventricular dysfunction. During a follow-up of 12 months post-
ICD implantation he experienced one episode of nonsustained fast
monomorphic VA without ICD therapy.
Any signiﬁcant arrhythmia was detected in 22 patients (73%). Fig. 2
shows the proportion of patients with a speciﬁc arrhythmia and
Appendix A provides an overview of detected arrhythmias per patient.
In 16 patients (53%) the detected arrhythmia was considered an action-
able event.Management included initiation or change of antiarrhythmic
drug therapy (n= 10, 33%), electrophysiology study (n= 6, 20%), ICD
implantation (n = 3, 10%), electrical cardioversion (n = 2, 7%), and
pacemaker implantation (n = 1, 3%).detection of ventricular arrhythmias in adults with congenital heart
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Fig. 1. Example ICM-detected episode of (A) ventricular tachycardia, (B) supraventricular tachycardia with pre-existing intraventricular conduction delay.
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The incidence of ICM-detected VA in a selected CHD population was
relatively high (27%). The ICM-detected VA contributed to the decision
to implant a prophylactic ICD in 10% of the study population. Further-
more, the detection of other arrhythmias by the ICM resulted in a signif-
icant change in clinical management in a majority of patients. The
present study is the ﬁrst prospective study focusing speciﬁcally on the
use of an ICM for risk stratiﬁcation in adults with CHD.Please cite this article as: R. Sakhi, R.M. Kauling, D.A. Theuns, et al., Early
disease using an insertab..., International Journal of Cardiology, https://do4.1. Risk of sudden death
Although the risk of SCD is higher in patients with CHD than in the
general population, the absolute risk is still relatively low (approxi-
mately 0.1% per year) [3]. This has stimulated the search for risk factors
whichmay help identify patients at risk for SCD, whomay beneﬁt from
a prophylactic ICD implantation. Important risk factors for SCD include
among others (recurrent) (non)sustained VA, inducible VA, atrial tachy-
arrhythmias, prolonged QRS duration, systemic ventricular dysfunction,detection of ventricular arrhythmias in adults with congenital heart
i.org/10.1016/j.ijcard.2020.02.009
Table 1
Baseline characteristics.
Characteristic N = 30
Age, years 38 ± 15
Gender, male 15 (50%)
Hypertension 8 (27%)
Diabetes mellitus 1 (3%)
Surgical repair 25 (83%)
Symptoms:
- Palpitations 12 (40%)
- (Near) Syncope 10 (33%)
- Palpitations and (near) syncope 6 (20%)
- Asymptomatic 2 (7%)
Congenital diagnosis:
Aortic coarctation 7 (23%)
- AVR 3 (10%)
Tetralogy of Fallot 5 (17%)
- Transannular patch 2 (7%)
ASD 5 (17%)
- Direct surgical closure of ASD 3 (10%)
TGA corrected by atrial switch 2 (7%)
TGA corrected by arterial switch 2 (7%)
Congenital corrected TGA 2 (7%)
- Tricuspid valvuloplasty 1 (3%)
VSD 2 (7%)
- VSD patch 2 (7%)
Other 5 (17%)
Systemic systolic ventricular function:
- Normal (EF ≥ 55%) 13 (43%)
- Mild impaired (EF 54–45%) 10 (33%)
- Moderate impaired (EF 36–44%) 7 (23%)
Electrocardiography:
- Sinus rhythm 27 (90%)
- Other rhythm 3 (10%)
- PR interval, if sinus rhythm, ms 180 ± 49
- QRS duration, ms 136 ± 31
- QRS duration N120 ms 17 (57%)
24–48 h Holter monitoring:
- b 1% PVCs 25 (83%)
- 1–10% PVCs 1 (3%)
- Non-sustained VA 6 (20%)
- Supraventricular tachycardia 2 (7%)
Cardiac medication: 19 (63%)
- ACE-inhibitor/ARB 8 (27%)
- Diuretics 3 (10%)
- Beta blocker 11 (37%)
- Amiodarone/Sotalol 3 (10%)
- Digoxin/calcium channel blocker 3 (10%)
- Oral anticoagulants 6 (23%)
Data is presented as n (%), mean ± SD. Abbreviations: ACE, angiotensin converting
enzyme; ARB, angiotensin receptor blocker; AVR, aortic valve replacement; ASD,
atrial septal defect; EF, ejection fraction; PVC, premature ventricular complex; TGA,
transposition of the great arteries; VSD, ventricle septal defect; VA, ventricular
arrhythmia.
Table 2
Overview ICM-detected arrhythmia episodes.
Total (n = 1689)
Symptom episode:a 538 (32%)
Sinus rhythm 473 (88%)
- Without ectopy 314 (58%)
- With PACs 19 (4%)
- With PVCs 140 (26%)
Atrial ﬁbrillation 33 (6%)
Regular small complex tachycardia 12 (2%)
Regular broad complex tachycardia 20 (4%)
Tachy episode:a 666 (39%)
Sinus rhythm 510 (77%)
- Without ectopy 268 (40%)
- With PACs 20 (3%)
- With PVCs 214 (32%)
- With noise 8 (1%)
Atrial ﬁbrillation 8 (1%)
Regular small complex tachycardia 118 (18%)
Regular broad complex tachycardia 30 (5%)
AF episode:a 213 (13%)
Sinus rhythm 18 (9%)
- With PACs 2 (b1%)
- With PVCs 16 (8%)
Atrial ﬁbrillation 180 (85%)
Small complex tachycardia 15 (7%)
- With intermittent AV-block 15 (7%)
Brady episode:a 147 (9%)
Sinus rhythm 41(28%)
- With undersensing due to PVCs 41(28%)
Sinus bradycardia 103 (70%)
AV block 3 (2%)
Pause episode:a 108 (6%)
Sinus rhythm 63 (58%)
- With sudden drop of R-wave 28 (26%)
- With small R-waves 17 (16%)
- With undersensing of PVCs 15 (14%)
- With loss of contact 3 (3%)
Sinus bradycardia 29 (27%)
AV block 3 (3%)
Sinus arrest or SA block 13 (12%)
AT episodes:a 17 (1%)
Atrial ﬁbrillation 10 (59%)
Sinus tachycardia 5 (29%)
Regular small complex tachycardia 2 (12%)
Data is presented as n (%). Abbreviations: AT, atrial tachycardia; AV, atrioventricular; PAC,
premature atrial complex; PVC, premature ventricular complex.
a Episode classiﬁcation by ICM.
Fig. 2. Proportion of patients with an ICM-detected arrhythmia.
4 R. Sakhi et al. / International Journal of Cardiology xxx (xxxx) xxxand subpulmonary ventricular dysfunction [4,14–17]. Despite the mul-
titude of identiﬁed risk factors, the indication for ICD implantation re-
mains challenging in clinical practice, especially regarding the
potential downside of ICD therapy [9–11]. Furthermore, risk stratiﬁca-
tion is not uniform for the CHD population. For example, inducible
sustained VA during programmed ventricular stimulation is useful for
risk stratiﬁcation in patients with TOF [7,8], but has not been demon-
strated to predict VA/SCD in other CHD populations [18].
4.2. Risk stratiﬁcation using ICM
In patients with certain high-risk features presenting with symp-
toms (i.e., syncope, near-syncope, palpitations), it is of importance for
both patients and caregivers to rule out VA. This can be attempted
using short-termmonitoring; however, when symptoms are infrequent
longer arrhythmiamonitoring is necessary. For this purpose, an ICM is a
valuable diagnostic tool for detecting paroxysmal arrhythmias aswell as
establishing a symptom-rhythm correlation.We provide data on the di-
agnostic yield of an ICM in a selected adult CHD population deemed atPlease cite this article as: R. Sakhi, R.M. Kauling, D.A. Theuns, et al., Early
disease using an insertab..., International Journal of Cardiology, https://dorisk for VA. The incidence of VAwas high in this population and resulted
in implantation of an ICD for primary prevention in 10% of the study
population. This is slightly higher than previous retrospective studies
in patients with CHD who received an ICM [19,20]. These studies fo-
cused on the overall diagnostic yield of an ICM and not speciﬁcally ondetection of ventricular arrhythmias in adults with congenital heart
i.org/10.1016/j.ijcard.2020.02.009
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nostic outcome of an ICM (Reveal or Reveal Plus, Medtronic Inc., Minne-
apolis, MN, USA) in a predominantly pediatric CHD population (median
age 15 years) [20]. In this study, 1 of 18 patients (6%) received an ICD
during a median follow-up of 19 months. The patient who received an
ICD was known with Ebstein's anomaly and developed monomorphic
VA at the age of 16 years. Amore recent retrospective study fromBoston
Children's Hospital included 34 patients with CHD and an ICM (Reveal
LINQ, Medtronic Inc., Minneapolis, MN, USA) [19]. In this study, 1 of
34 patients (3%) received an ICD during a median duration of follow-
up of 11.8 months. The patient who received an ICD was a patient
with Fontan circulation who received an ICM at the age of 32 years.
Other series reporting the use of ICM in patients with CDH are smaller
and mostly performed in a pediatric population [21–28].
4.3. Cost-beneﬁt of ICMs for risk stratiﬁcation
Besides the use of an ICM for risk stratiﬁcation, the ICM detected a
signiﬁcant arrhythmia in 73% of the population and this led to a change
in clinicalmanagement in 53%of patients. Therefore, an ICMcan be used
to titrate medication and identify candidates for an electrophysiologic
procedure (i.e., pacemaker, ICD or electrophysiological study). An im-
portant aspect is the ability to differentiate between benign (near)syn-
cope and arrhythmogenic (near)syncope. Providing reassurance to a
symptomatic patient is valuable in daily clinical practice.
Although the use of ICMs for risk stratiﬁcation seems promising,
there are some factors which should be considered such as device
costs, data overload, clinical relevance of device-detected VA and med-
ical overuse. The issue of data overload is exempliﬁed by the recording
of N1600 episodes in 30 patients in a relatively short follow-up period
in our study population. This requires a proper logistic organization
with a dedicated telemonitoring staff. There is some controversy with
regard to the clinical relevance of device-detected arrhythmias, espe-
cially for atrial ﬁbrillation [12]. With regard to the clinical relevance of
device-detected VA, it is important to stress that in our population the
majority of VA episodeswere detected as patient-activated episodes, in-
dicating that the patient experienced symptoms. Koyak et al. previously
identiﬁed that symptomatic but not asymptomatic nonsustained VA
was associated with appropriate ICD therapy in TOF patients who re-
ceive an ICD for primary prevention [29].
4.4. Study limitations
A limitation of the present study is the small size and lack of a control
group. Therefore, no conclusion can bemade regarding the incremental1
2
3
4
5
6
7
Please cite this article as: R. Sakhi, R.M. Kauling, D.A. Theuns, et al., Early
disease using an insertab..., International Journal of Cardiology, https://dovalue of an ICM compared to standard clinical practice with intermit-
tent Holter monitoring. Ideally, a randomized clinical trial would be
conducted where patients are randomized to an ICM or conventional
follow-up. Obstacles for such a clinical trial are the heterogeneity of
the population and challenges in deﬁning appropriate endpoints. In
this regard, it is important to stress that our study population was
a highly selected population. The usefulness of an ICM may not
apply to an unselected CHD population. Finally, the classiﬁcation of
broad complex tachycardia as either VA or SVT can be challenging
considering that only a single surface EGM is available. To reduce
the risk of misclassiﬁcation, difﬁcult EGMs were reevaluated by an
electrophysiologist.
5. Conclusion
There was a high incidence of ICM-detected VA in adults with
CHD who were deemed at risk of VA. ICM results led to implanta-
tion of an ICD in 10% of the study population. The detection of ar-
rhythmias by the ICM led to important changes in the clinical
management of patients. Our prospective pilot study suggests
that the use of ICMs for risk stratiﬁcation in selected adults with
CHD is helpful.
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Underlying Surgical status Age at QRS Reason for ICM
diagnosis repair
(years)
duration
(ms)detection of ventric
i.org/10.1016/j.ijcardAge at ICM
implantation
(years)ular arrhythmi
.2020.02.009FU with
ICM
(months)as in adulICM-detected
arrhythmiats with congeICM-guided
therapyAortic
coarctationSurgical repair, AVR 8 190 Syncope, bifascicular block with
ﬁrst-degree AV block56 10 Sinus arrest AADAortic
coarctationSurgical repair 3 117 Prior NSVT (asymptomatic) 26 12 NSVT ConservativeAortic
coarctationSurgical repair, PDA
closure11 148 Syncope, mild systemic ventricular
dysfunction71 15 SVT, AF, AFL Ablation,
ECV, AADAortic
coarctationSurgical repair, AVR,
MVRb1 109 Palpitations, exercise-induced PVCs, mild
systemic ventricular dysfunction19 3 NSVT, SVT, SA
block, AFDDD-ICD,
AADAortic
coarctationSurgical repair, PDA
closure14 124 Palpitations, syncope, prior NSVT, mild sys-
temic ventricular dysfunction19 32 SVT AblationAortic
coarctationSurgical repair 38 81 Palpitations 41 1Aortic
coarctationSurgical repair, AVR 10 174 Palpitations, mild systemic ventricular
dysfunction55 21(continued on next page)nital heart
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implantation
(years)cular arrhythmi
.2020.02.009FU with
ICM
(months)as in adulICM-detected
arrhythmiats with congeICM-guided
therapyTOF Total repair, PVR 30 180 Palpitations, QRS 180 ms 52 17 AF, AV block Conservative
TOF Total repair
(transannular patch),
PVRb1 176 Palpitations, mild systemic ventricular
dysfunction33 17 SVT,
BradycardiaConservative0 TOF Total repair
(Hancock conduit)11 155 Palpitations, near syncope 41 3 NSVT DDD-ICD1 TOF Total repair 8 176 Near syncope, prior NSVT 39 21
2 TOF Total repair
(transannular patch)
5 161 Palpitations, syncope 25 323 ASD Surgical closure ASD,
PV repair11 114 Palpitations, near syncope, mild systemic
ventricular dysfunction56 4 SVT AAD, EPS4 ASD Percutaneous ASD
closure27 168 Syncope, mild systemic ventricular
dysfunction36 31 SVT,
bradycardiaAAD, EPS5 ASD 106 Syncope 74 3 AF, AV block Pacemaker
6 ASD Surgical closure ASD,
PV repair, TV repair
8 109 Palpitations, mild systemic ventricular
dysfunction
43 16 AF, SVT Conservative7 ASD Surgical closure ASD,
TV repair20 116 Near syncope, mild systemic ventricular
dysfunction24 108 d-TGA Mustard repair 5 146 Near syncope, moderate systemic
ventricular dysfunction, exercise-induced
PVCs39 15 AV block Conservative9 d-TGA Mustard repair 4 99 Palpitations, moderate systemic ventricular
dysfunction47 40 d-TGA Arterial switch and
VSD closure (patch)b1 136 Palpitations, moderate systemic ventricular
dysfunction29 21 SVT, NSVT Conservative1 d-TGA Arterial switch, VSD
closure (patch)b1 118 Palpitations, prior NSVT 18 36 SVT, NSVT AAD2 cc-TGA TV repair 40 152 Syncope, prior SVT, moderate systemic ven-
tricular dysfunction43 18 NSVT, AF,
BradycardiaDDD-ICD3 cc-TGA 97 Palpitations, moderate systemic ventricular
dysfunction29 30 SVT, AFL Ablation4 VSD VSD closure (patch)
and PDA closureb1 104 Near syncope, prior NSVT 20 29 NSVT, SVT, AF AAD5 VSD VSD closure (patch)
and ASD repair2 118 Palpitations, prior NSVT 19 12 NSVT, SVT AAD6 Tricuspid
atresiaTCPC with lateral
tunnel11 130 Palpitations, near syncope 50 2 SVT AAD,
Ablation7 Bicuspid
aortic valve88 Exercise-induced PVCs (asymptomatic) 41 27 Symptomatic
PVCsAAD8 DOLV Rastelli repair 11 174 Palpitations, prior SVT, moderate systemic
ventricular dysfunction43 12 AFL ECV9 Congenital
PV stenosisPV and TV repair 11 153 Palpitations, near syncope, mild systemic
ventricular dysfunction20 190 Ebstein's
anomaly151 Near syncope, moderate systemic
ventricular dysfunction24 16Abbreviations: AAD, antiarrhythmic drug; AF, atrialﬁbrillation;AFL, atrialﬂutter; ASD, atrial septal defect; AV, atrioventricular; AVR, aortic valve replacement; cc-TGA, congenital corrected
transposition of the great arteries; d-TGA, d-transposition of the great arteries; DOLV, double outlet left ventricle; ECV, electrical cardioversion; EPS, electrophysiology study; ICD, implant-
able cardioverter-deﬁbrillator; ICM, insertable cardiacmonitor; FU, follow-up;MVR,mitral valve replacement; NSVT, nonsustained ventricular tachycardia; PDA, patent ductus arteriosus;
PV, pulmonary valve; PVC, premature ventricular complex; SA, sino-atrial; SVT, supraventricular tachycardia; TCPC, total cavopulmonary connection; TOF, tetralogy of Fallot; TV, tricuspid
valve; VSD, ventricular septal defect.References
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